Compare CSTL & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSTL | JQC |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 705.1M |
| IPO Year | 2019 | N/A |
| Metric | CSTL | JQC |
|---|---|---|
| Price | $32.37 | $4.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $45.50 | N/A |
| AVG Volume (30 Days) | 310.1K | ★ 584.6K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | N/A |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $17.72 | $4.62 |
| 52 Week High | $44.28 | $5.46 |
| Indicator | CSTL | JQC |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 40.91 |
| Support Level | $22.88 | $4.69 |
| Resistance Level | $34.23 | $4.88 |
| Average True Range (ATR) | 1.54 | 0.03 |
| MACD | -0.42 | -0.00 |
| Stochastic Oscillator | 23.40 | 0.00 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.